Published in Cancer Weekly, April 24th, 2006
A group of oncologists in Texas conducted a study to evaluate "the safety of bevacizumab with capecitabine-based chemoradiotherapy."
"Patients with inoperable pancreatic adenocarcinoma received bevacizumab 2 weeks before radiotherapy (50.4 Gy treating the primary tumor and gross adenopathy), every 2 weeks during radiotherapy (12 patients each at 2.5, 5.0, 7.5, and 10 mg/kg), and after radiotherapy until disease progression," explained C.H. Crane and coauthors at the M.D. Anderson Cancer Center in Houston.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.